CDC advisory panel says U.S. should resume Johnson & Johnson vaccine
Resuming the vaccine is "in the best public health interest" of the country, panel member claims.
The Facts Inside Our Reporter’s Notebook
The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices said on Friday that the United States should resume dispensing the Johnson & Johnson COVID-19 vaccine, a little over a week after federal health authorities recommended a pause in the vaccine due to concerns over potential blood clots.
CDC Director Rochelle Walensky will decide whether or not to accept the panel's recommendation. Walensky herself said on Friday that she anticipates that she'll make the decision "quickly."
The panel voted 10-4, with one abstention, in favor of resuming the shots, though it advised that a warning about the blood clots should accompany the administration of the vaccine.
About 40% of the U.S. has received at least one dose of a COVID-19 vaccine as of this week.
News, Not Noise
- House Republicans ask Secretary of State for documents related to Wuhan coronavirus lab
- New NASA head pledges to shoot for Trump 2024 deadline of putting another man on the moon
- Arizona Senate, Maricopa Co. mull next steps in standoff over routers subpoenaed in vote audit
- Fauci's agency spent over $400k on experiments grafting aborted fetal scalps onto mice and rats
- Minnesota school district adopts Black Lives Matter slogan as privileged 'government speech'